Consun Pharmaceutical Group Limited
1681.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$12.46B
Close$
Share Statistics
| Market cap | $12.46 Billion |
|---|---|
| Enterprise Value | $11.45 Billion |
| Dividend Yield | $0.73 (5.25%) |
| Earnings per Share | $1.26 |
| Beta | 0.48 |
| Outstanding Shares | 841,130,000 |
Return
| Return on Equity | 45.71% |
|---|---|
| Return on Assets | 31.86% |
| Return on Invested Capital | 45.05% |
Valuation & Multiples
| P/E Ratio | 9.16 |
|---|---|
| PEG | 51.41 |
| Price to Sales | 1.86 |
| Price to Book Ratio | 2.48 |
| Enterprise Value to Revenue | 1.67 |
| Enterprise Value to EBIT | 4.86 |
| Enterprise Value to Net Income | 5 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 26, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$2.03 B
Average shareholder expectationNext Earnings Call
Expected Date
March 24, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$2.17 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Consun Pharmaceutical Group Limited
2,847 employees
CEO: Meng An Consun Pharmaceutical Group Limited operates as an investment holding company, primarily engaged in the research, development, manufacturing, and distribution of traditional Chinese medicines and sophisticated medical contrast agents thr...